{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:39:43Z","timestamp":1790962783640,"version":"4.1.0"},"reference-count":55,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01-DK105448"],"award-info":[{"award-number":["R01-DK105448"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UL1TR001105"],"award-info":[{"award-number":["UL1TR001105"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Despite several reports of familial partial lipodystrophy (FPLD) type 2 (FPLD2) due to heterozygous LMNA variants and FPLD3 due to PPARG variants, the phenotypic differences among them remain unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare the body fat distribution, metabolic parameters, and prevalence of metabolic complications between FPLD3 and FPLD2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective, cross-sectional comparison of patients from 2 tertiary referral centers\u2014UT Southwestern Medical Center and the National Institute of Diabetes and Digestive and Kidney Diseases. A total of 196 females and 59 males with FPLD2 (age 2-86 years) and 28 females and 4 males with FPLD3 (age 9-72 years) were included. The main outcome measures were skinfold thickness, regional body fat by dual-energy X-ray absorptiometry (DXA), metabolic variables, and prevalence of diabetes mellitus and hypertriglyceridemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Compared with subjects with FPLD2, subjects with FPLD3 had significantly increased prevalence of hypertriglyceridemia (66% vs 84%) and diabetes (44% vs 72%); and had higher median fasting serum triglycerides (208 vs 255\u2005mg\/dL), and mean hemoglobin A1c (6.4% vs 7.5%). Compared with subjects with FPLD2, subjects with FPLD3 also had significantly higher mean upper limb fat (21% vs 27%) and lower limb fat (16% vs 21%) on DXA and increased median skinfold thickness at the anterior thigh (5.8 vs 11.3\u2005mm), calf (4 vs 6\u2005mm), triceps (5.5 vs 7.5\u2005mm), and biceps (4.3 vs 6.8\u2005mm).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Compared with subjects with FPLD2, subjects with FPLD3 have milder lipodystrophy but develop more severe metabolic complications, suggesting that the remaining adipose tissue in subjects with FPLD3 may be dysfunctional or those with mild metabolic disease are underrecognized.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvac155","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T18:26:12Z","timestamp":1665512772000},"source":"Crossref","is-referenced-by-count":31,"title":["Phenotypic Differences Among Familial Partial Lipodystrophy Due to <i>LMNA<\/i> or <i>PPARG<\/i> Variants"],"prefix":"10.1210","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4014-2831","authenticated-orcid":false,"given":"Chandna","family":"Vasandani","sequence":"first","affiliation":[{"name":"Division of Nutrition and Metabolic Diseases and the Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center , Dallas, TX 75390 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Population and Data Sciences, UT Southwestern Medical Center , Dallas, TX 75390 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-870X","authenticated-orcid":false,"given":"Hilal","family":"Sekizkardes","sequence":"additional","affiliation":[{"name":"National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, MD 20892 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J","family":"Brown","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-6986","authenticated-orcid":false,"given":"Abhimanyu","family":"Garg","sequence":"additional","affiliation":[{"name":"Division of Nutrition and Metabolic Diseases and the Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center , Dallas, TX 75390 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"issue":"12","key":"2022111514191709300_bvac155-B1","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2022111514191709300_bvac155-B2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology"},{"issue":"12","key":"2022111514191709300_bvac155-B3","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"2022111514191709300_bvac155-B4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.semcdb.2013.12.015","article-title":"Nuclear envelope-related lipodystrophies","volume":"29","author":"Guenantin","year":"2014","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"2022111514191709300_bvac155-B5","first-page":"408","article-title":"A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy","volume":"87","author":"Agarwal","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2022111514191709300_bvac155-B6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1172\/JCI28003","article-title":"PPAR gamma and human metabolic disease","volume":"116","author":"Semple","year":"2006","journal-title":"J Clin Invest"},{"issue":"12","key":"2022111514191709300_bvac155-B7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/ng.3700","article-title":"Prospective functional classification of all possible missense variants in PPARG","volume":"48","author":"Majithia","year":"2016","journal-title":"Nat Genet"},{"key":"2022111514191709300_bvac155-B8","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1210\/clinem\/dgaa137","article-title":"Diagnostic value of anthropometric measurements for familial partial lipodystrophy, Dunnigan variety","volume":"105","author":"Vasandani","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2022111514191709300_bvac155-B9","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1210\/jc.2018-02787","article-title":"Efficacy of metreleptin treatment in familial partial lipodystrophy due to PPARG vs LMNA pathogenic variants","volume":"104","author":"Sekizkardes","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2022111514191709300_bvac155-B10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","article-title":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","volume":"72","author":"Akinci","year":"2017","journal-title":"Metabolism"},{"issue":"7","key":"2022111514191709300_bvac155-B11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-011-2142-4","article-title":"Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARgamma mutation (Y151C)","volume":"54","author":"Visser","year":"2011","journal-title":"Diabetologia"},{"issue":"5","key":"2022111514191709300_bvac155-B12","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1210\/jc.2006-1807","article-title":"Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma","volume":"92","author":"Monajemi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2022111514191709300_bvac155-B13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.bbalip.2019.02.002","article-title":"Gene-gene and gene-environment interactions in lipodystrophy: lessons learned from natural PPAR\u03b3 mutants","volume":"1864","author":"Broekema","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"6764","key":"2022111514191709300_bvac155-B14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"issue":"2","key":"2022111514191709300_bvac155-B15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1172\/JCI200420964","article-title":"Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma","volume":"114","author":"Tsai","year":"2004","journal-title":"J Clin Invest"},{"key":"2022111514191709300_bvac155-B16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fgene.2017.00079","article-title":"LMNA Sequences of 60,706 unrelated individuals reveal 132 novel missense variants in A-type lamins and suggest a link between variant p.G602S and type 2 diabetes","volume":"8","author":"Florwick","year":"2017","journal-title":"Front Genet"},{"key":"2022111514191709300_bvac155-B17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-800892-8.00023-3","volume-title":"Genetic Diagnosis of Endocrine Disorders","author":"Garg","year":"2016","edition":"2nd ed"},{"issue":"12","key":"2022111514191709300_bvac155-B18","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1210\/jc.2007-0654","article-title":"New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome","volume":"92","author":"Decaudain","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2022111514191709300_bvac155-B19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0002-9343(02)01070-7","article-title":"Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A\/C gene","volume":"112","author":"Garg","year":"2002","journal-title":"Am J Med"},{"issue":"1","key":"2022111514191709300_bvac155-B20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1399-0004.2009.01350.x","article-title":"Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A\/C mutations","volume":"78","author":"Subramanyam","year":"2010","journal-title":"Clin Genet"},{"issue":"4","key":"2022111514191709300_bvac155-B21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1212\/WNL.59.4.620","article-title":"Lamin A\/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy","volume":"59","author":"van der Kooi","year":"2002","journal-title":"Neurology"},{"issue":"3","key":"2022111514191709300_bvac155-B22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-12-0268","article-title":"Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations","volume":"167","author":"Mory","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2022111514191709300_bvac155-B23","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/diacare.26.5.1350","article-title":"Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety","volume":"26","author":"Haque","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"2022111514191709300_bvac155-B24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/hmg\/9.1.109","article-title":"Nuclear lamin A\/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy","volume":"9","author":"Cao","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2022111514191709300_bvac155-B25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/72807","article-title":"LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy","volume":"24","author":"Shackleton","year":"2000","journal-title":"Nat Genet"},{"issue":"4","key":"2022111514191709300_bvac155-B26","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/302836","article-title":"Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A\/C","volume":"66","author":"Speckman","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2022111514191709300_bvac155-B27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1091\/mbc.e12-07-0527","article-title":"Lamin A tail modification by SUMO1 is disrupted by familial partial lipodystrophy-causing mutations","volume":"24","author":"Simon","year":"2013","journal-title":"Mol Biol Cell"},{"issue":"7","key":"2022111514191709300_bvac155-B28","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1210\/jc.2005-2746","article-title":"A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2","volume":"91","author":"Morel","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2022111514191709300_bvac155-B29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40246-018-0167-1","article-title":"Whole-exome sequencing identifies novel pathogenic mutations and putative phenotype-influencing variants in Polish limb-girdle muscular dystrophy patients","volume":"12","author":"Fichna","year":"2018","journal-title":"Hum Genomics"},{"issue":"3","key":"2022111514191709300_bvac155-B30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/6799","article-title":"Mutations in the gene encoding lamin A\/C cause autosomal dominant Emery-Dreifuss muscular dystrophy","volume":"21","author":"Bonne","year":"1999","journal-title":"Nat Genet"},{"issue":"4","key":"2022111514191709300_bvac155-B31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00125-004-1360-4","article-title":"Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene","volume":"47","author":"Savage","year":"2004","journal-title":"Diabetologia"},{"issue":"2","key":"2022111514191709300_bvac155-B32","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.4158\/ACCR-2019-0366","article-title":"Unusual presentations of LMNA-associated lipodystrophy with complex phenotypes and generalized fat loss: when the genetic diagnosis uncovers novel features","volume":"6","author":"de Andrade","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"2022111514191709300_bvac155-B33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fendo.2018.00458","article-title":"Homozygous and heterozygous nuclear lamin A p.R582C mutation: different lipodystrophic phenotypes in the same kindred","volume":"9","author":"Montenegro RM","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2022111514191709300_bvac155-B34","first-page":"59","article-title":"Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of missense mutations in lamin a\/c gene","volume":"86","author":"Garg","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2022111514191709300_bvac155-B35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mus.20293","article-title":"Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A\/C gene","volume":"31","author":"Mercuri","year":"2005","journal-title":"Muscle Nerve"},{"issue":"6","key":"2022111514191709300_bvac155-B36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"9","key":"2022111514191709300_bvac155-B37","doi-asserted-by":"crossref","first-page":"e7038","DOI":"10.1371\/journal.pone.0007038","article-title":"Dual energy X-ray absorptiometry body composition reference values from NHANES","volume":"4","author":"Kelly","year":"2009","journal-title":"PLoS One"},{"issue":"8","key":"2022111514191709300_bvac155-B38","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.ejrad.2016.04.004","article-title":"DXA: technical aspects and application","volume":"85","author":"Bazzocchi","year":"2016","journal-title":"Eur J Radiol"},{"issue":"4","key":"2022111514191709300_bvac155-B39","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1210\/jc.2018-01922","article-title":"Regional body fat changes and metabolic complications in children with Dunnigan lipodystrophy-causing LMNA variants","volume":"104","author":"Patni","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2022111514191709300_bvac155-B40","first-page":"1776","article-title":"Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety)","volume":"85","author":"Garg","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2022111514191709300_bvac155-B41","author":"Vasandani"},{"issue":"7","key":"2022111514191709300_bvac155-B42","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1194\/jlr.R700004-JLR200","article-title":"Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism","volume":"48","author":"Hegele","year":"2007","journal-title":"J Lipid Res"},{"issue":"1","key":"2022111514191709300_bvac155-B43","first-page":"170","article-title":"Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)","volume":"84","author":"Garg","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2022111514191709300_bvac155-B44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/osp4.319","article-title":"Visceral fat does not contribute to metabolic disease in lipodystrophy","volume":"5","author":"Malandrino","year":"2019","journal-title":"Obes Sci Pract"},{"issue":"6","key":"2022111514191709300_bvac155-B45","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1172\/JCI1235","article-title":"Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats","volume":"101","author":"Okuno","year":"1998","journal-title":"J Clin Invest"},{"issue":"4","key":"2022111514191709300_bvac155-B46","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/hmg\/ddi480","article-title":"Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy","volume":"15","author":"Boguslavsky","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2022111514191709300_bvac155-B47","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000760","article-title":"Diseases of the nuclear envelope","volume":"2","author":"Worman","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"12","key":"2022111514191709300_bvac155-B48","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1464-5491.2002.00796.x","article-title":"Post-mortem findings in familial partial lipodystrophy, Dunnigan variety","volume":"19","author":"Haque","year":"2002","journal-title":"Diabet Med"},{"issue":"2","key":"2022111514191709300_bvac155-B49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1464-5491.2009.02909.x","article-title":"Post-mortem findings in Dunnigan-type familial partial lipodystrophy","volume":"27","author":"Ludtke","year":"2010","journal-title":"Diabet Med"},{"key":"2022111514191709300_bvac155-B50","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/cells9051284","article-title":"In-vitro-generated hypertrophic-like adipocytes displaying PPARG isoforms unbalance recapitulate adipocyte dysfunctions in vivo","volume":"9","author":"Aprile","year":"2020","journal-title":"Cells"},{"key":"2022111514191709300_bvac155-B51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"2022111514191709300_bvac155-B52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cmet.2006.09.003","article-title":"Non-DNA binding, dominant-negative, human PPAR\u03b3 mutations cause lipodystrophic insulin resistance","volume":"4","author":"Agostini","year":"2006","journal-title":"Cell Metab"},{"issue":"8","key":"2022111514191709300_bvac155-B53","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1074\/jbc.275.8.5754","article-title":"A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis","volume":"275","author":"Gurnell","year":"2000","journal-title":"J Biol Chem"},{"issue":"6","key":"2022111514191709300_bvac155-B54","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.celrep.2018.10.035","article-title":"PPAR\u03b3\u03945, a naturally occurring dominant-negative splice isoform, impairs PPAR\u03b3 function and adipocyte differentiation","volume":"25","author":"Aprile","year":"2018","journal-title":"Cell Rep"},{"issue":"2","key":"2022111514191709300_bvac155-B55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/db19-0447","article-title":"Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort","volume":"69","author":"Gonzaga-Jauregui","year":"2020","journal-title":"Diabetes"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvac155\/46441885\/bvac155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/12\/bvac155\/47043889\/bvac155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/12\/bvac155\/47043889\/bvac155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T14:20:16Z","timestamp":1668522016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvac155\/6758444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,10,26]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvac155","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,10,11]]},"article-number":"bvac155"}}